Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > OMER > Summary

Omeros Corporation
(OMER)

5.69USD   Down 0.13 (2.23%)   
At 2:30AM IST
 Omeros Corporation (NGM:OMER) Delayed quote data 
[Chart]
1d  5d  3m  6m 
Last Trade: 5.69USD
Trade Time:2:30AM IST
Change:Down 0.13 (2.23%) 
Prev Close:5.82
Open:5.83
Bid:4.30 x 600
Ask:N/A
1y Target Est:11.80
Day's Range:5.65 - 5.86
52wk Range:5.27 - 9.49
Volume:26,725
Avg Vol (3m):45,754
Market Cap:121.04M
P/E (ttm):N/A
EPS (ttm):-7.48
Div & Yield:N/A (N/A%)
Add OMER to Portfolio   Download Data

HEADLINES

 
•Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program - PR Newswire  - Thu, Jan 28
•After A Sluggish Year, VCs Eye Improvement - Investor's Business Daily  - Sat, Jan 9
•IPO comeback in 2009 sets stage for busy 2010 - AP  - Fri, Jan 1
•The Worst IPOs Of 2009 - Investopedia  - Wed, Dec 16
•Worst IPOs of 2009: Biggest Stock Flops - TheStreet.com  - Tue, Dec 15
•OMEROS CORP Files SEC form 8-K, Change in Directors or Principal Officers - EDGAR Online  - Wed, Dec 9
•Coverage initiated on Omeros by Needham - Briefing.com  - Tue, Dec 1
•New Star Analyst Rankings for Omeros Corporation - StarMine  - Sun, Nov 22
•OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition - EDGAR Online  - Fri, Nov 20
•Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights - PR Newswire  - Fri, Nov 20
» More Headlines for OMER...

ANALYST

 
EPS Est (next year) (Dec-09) :-1.44
EPS Est (in 2 years) (Dec-10) :-1.41
Avg Rec (current)*:1.6
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system.

» Full Company Profile